A Randomized, Double-Blind, Placebo Controlled, Sponsor Open, Phase 1b Study To Examine The Adjunctive Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia

Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Sponsor Open, Phase 1b Study To Examine The Adjunctive Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2013

At a glance

  • Drugs Mardepodect (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 11 Oct 2013 Planned End Date changed from 1 Sep 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov record.
    • 11 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top